Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance

Molecular Cancer Therapeutics

Volumn 10, Issue 5, 2011, Pages 761-769

  Huang, I Ping ^a,b   Sun, Shu Pin ^a   Cheng, Shih Hsun ^a   Lee, Chia Hung ^a   Wu, Chia Yan ^a   Yang, Chung Shi ^a   Lo, Leu Wei ^a   Lai, Yiu Kay ^b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; HYDRAZONE DERIVATIVE; MESOPOROUS SILICA NANOPARTICLE HYDRAZONE; NANOPARTICLE; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HUMANS; HYDRAZONES; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; P-GLYCOPROTEIN; SILICON DIOXIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956028537     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0884     Document Type: Article

References (36)

1. Duhem C, Ries F, Dicato M. What does multidrug resistance (MDR) expression mean in the clinic?Oncologist 1996;1:151-8.
2. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-83.
3. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J Obstet Gynecol 2009;48:239-44.
4. Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009;14:1067-74.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
6. Shabbits JA, Krishna R, Mayer LD. Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 2001;1:585-94.
7. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009;69:3918-26.
8. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005;103:405-18.
9. Somogyi A, Eichelbaum M, Gugler R. Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol 1982;22:85-90.
10. Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009;5:2673-7.
11. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007;3:1341-6.
12. Lin YS, Tsai CP, Huang HY, Kuo CT, Hung Y, Huang DM, et al. Well-ordered mesoporous silica nanoparticles as cell markers. Chem Mater 2005;17:4570-3.
13. Cheng S-H, Lee C-H, Chen M-C, Souris JS, Tseng F-G, Yang C-S, et al. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics-the trio of imaging, targeting and therapy. J Mater Chem 2010;20:6149-57.
14. Lee C-H, Lo L-W, Mou C-Y, Yang C-S. Synthesis and characterization of positive-charge functionalized mesoporous silica nanoparticles for oral drug delivery of an anti-inflammatory drug. Adv Funct Mater 2008;18:3283-92.
15. Cheng S-H, Lee C-H, Yang C-S, Tseng F-G, Mou C-Y, Lo L-W. Mesoporous silica nanoparticles functionalized with an oxygen-sensing probe for cell photodynamic therapy: potential cancer theranostics. J Mater Chem 2009;19:1252-7.
16. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010;4:4539-50.
17. Lee CH, Cheng SH, Huang IP, Souris JS, Yang CS, Mou CY, et al. Intracellular pH-responsive mesoporous silica nanoparticles for controlled release of anticancer chemotherapeutics. Angew Chem Int Ed 2010;49:8214-19.
18. Traunecker HC, Stevens MC, Kerr DJ, Ferry DR. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells. Br J Cancer 1999;81:942-51.
19. Yi Y, Kim JH, Kang HW, Oh HS, Kim SW, Seo MH. A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution. Pharm Res 2005;22:200-8.
20. Filipits M. Mechanisms of cancer: multidrug resistance. Drug Discov Today: Dis Mech 2004;1:229-34.
21. Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999;17:94-5.
22. Harker WG, Bauer D, Etiz BB, Newman RA, Sikic BI. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res 1986;46:2369-73.
23. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 1979;39:2200-3.
24. Roepe PD. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Biochemistry 1992;31:12555-64.
25. Lampidis TJ, Krishan A, Planas L, Tapiero H. Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv 1986;3:251-9.
26. He Q, Shi J, Chen F, Zhu M, Zhang L. An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials 2010;31:3335-46.
27. Klichko Y, Liong M, Choi E, Angelos S, Nel AE, Stoddart JF, et al. Mesostructured silica for optical functionality, nanomachines, and drug delivery. J Am Ceram Soc 2009;92:s2-s10.
28. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, et al. Multi-functional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008;2:889-96.
29. Radu DR, Lai CY, Jeftinija K, Rowe EW, Jeftinija S, Lin VS. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J Am Chem Soc 2004;126:13216-7.
30. Slowing II, Trewyn BG, Lin VS. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. J Am Chem Soc 2007;129:8845-9.
31. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008;60:1278-88.
32. Slowing I, Trewyn BG, Lin VS. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc 2006;128:14792-3.
33. Neidle S. The molecular basis for the action of some DNA-binding drugs. Prog Med Chem 1979;16:151-221.
34. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-8.
35. Wang Y, Arriaga EA. Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques. Cancer Lett 2008;262:123-32.
36. Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 2003;3:321-38.